SB's Denavir Cleared For Cold Sores In USA
SmithKline Beecham's antiviral drug Denavir (penciclovir) has been approved by the US Food and Drug Administration for the treatment of recurrent cold sores in adults. It is the first and only topical antiviral cream to be cleared by the FDA for this indication.
Denavir will be marketed by SmithKline Beecham Consumer Healthcare, and will be available by prescription. The drug was recently launched in the UK under the brandname Vectavir for the same indication and is currently under review by regulatory authorities in other major markets.
SB has forecast a launch of the product in the USA in early 1997, and is reportedly in negotiations with the FDA regarding potential over-the-counter use of the drug for cold sores.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze